Literature DB >> 26468405

Long-term assessment of no evidence of disease activity in relapsing-remitting MS.

Nicola De Stefano1, Maria Laura Stromillo2, Antonio Giorgio2, Marco Battaglini2, Maria Letizia Bartolozzi2, Maria Pia Amato2, Maria Pia Sormani2.   

Abstract

Mesh：

Year:  2015        PMID： 26468405     DOI： 10.1212/WNL.0000000000002105

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

Review 1.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 2.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

3.  Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  J Burman; K Kirgizov; K Carlson; M Badoglio; G L Mancardi; G De Luca; B Casanova; J Ouyang; R Bembeeva; J Haas; P Bader; J Snowden; D Farge
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

4.  Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.

Authors:  Hiroaki Yokote; Tomoyuki Kamata; Shuta Toru; Nobuo Sanjo; Takanori Yokota
Journal:  Neurol Sci       Date:  2018-07-04       Impact factor: 3.307

5.  Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.

Authors:  Subhash Tummala; Tarun Singhal; Vinit V Oommen; Gloria Kim; Fariha Khalid; Brian C Healy; Rohit Bakshi
Journal:  Int J MS Care       Date:  2017 May-Jun

Review 6.  Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis.

Authors:  Olga Ciccarelli; Alan Thompson
Journal:  Nat Rev Neurol       Date:  2016-01-29       Impact factor: 42.937

7.  No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Authors:  Eva Havrdová; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Fred Lublin; Krzysztof Selmaj; Anthony Traboulsee; Shibeshih Belachew; Iain Bennett; Regine Buffels; Hideki Garren; Jian Han; Laura Julian; Julie Napieralski; Stephen L Hauser; Gavin Giovannoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-03-12

8.  Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.

Authors:  Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

9.  Population-based study of "no evident disease activity" in MS.

Authors:  Natalie E Parks; Sean J Pittock; Jay Mandrekar; Orhun H Kantarci; Claudia F Lucchinetti; Brian G Weinshenker; B Mark Keegan; W Oliver Tobin; Jan-Mendelt Tillema; Michel Toledano; Eoin P Flanagan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.